All In Biotech

Drug Trial Radar · NCT05392179

A Study in Subjects With Retinitis Pigmentosa

An Open-label, Phase II Study of ADX-2191 in Subjects With Retinitis Pigmentosa

Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

8

Actual

Start

Jul 14, 2022

Primary completion

Jun 23, 2023

Study completion Jun 23, 2023

Sponsor

Lead sponsor
Aldeyra Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.

Conditions

  • Retinitis Pigmentosa

Interventions

  • ADX-2191Drug

    Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of three injections. Evaluation through week 16.

  • ADX-2191Drug

    Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of six injections. Evaluation through week 16.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Serious Adverse EventsTime frame: The safety assessment period was 16 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Duke Eye Center

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.